Тикагрелор как новая возможность повышения эффективности лечения острого коронарного синдрома: место в современных клинических рекомендациях

1. Wallentin L, Becker RC, Budaj A et al. for the PLATO Investigators. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361: 1045–57.
2. Steg PG, James S, Harrington RA et al. for the PLATO Study Group. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis. Circulation 2010; 122: 2131–41.
3. Brilique: EPAR – Product information. http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Product_Information/human/001241/WC500100494.pdf
4. Brilinta: full prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/ 022433s000lbl.pdf
5. James SK, Roe MT, Cannon CP et al. for the PLATO study group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient Outcomes (PLATO) Trial. BMJ 2011; 342. d3527 doi: 10.1136/bmj.d3527.
6. Held C, Åsenblad N, Bassand JP et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. JACC 2011; 57. doi:10.1016/ j.jacc.2010.10.029
7. James S, Budaj A, Aylward P et al. Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function. Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2010; 122: 1056–67.
8. James S, Angiolillo DJ, Cornel JH et al. for the PLATO study group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010: doi:10.1093/ eurheartj/ehq325.
9. Mahaffey KW, Wojdyla DM, Carroll K et al. on behalf of the PLATO Investigators Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2011; 124: 572–81.
10. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011. doi:10.1093/eurheartj/ehr236.
11. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 104–23.
12. Wenger NK. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): Highlights for the Clinician. Clin Cardiol 2012; 35: 3–8.
13. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909–345.
14. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update)ю A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271–306.
15. Smith SC, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. A Guideline From the American Heart Association and American College of Cardiology Foundation. Endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. Circulation. 2011;124. Доступно в интернете на сайте http://circ.ahajournals.org/content/early/2011/11/01/CIR.0b013e318235eb4d.citation
16. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010; 31: 2501–55.
17. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A Report of the American College of Cardiology Foundation/American Heart Association. Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. JACC 2011; 124. doi:10.1016/j.jacc.2011.08.007
18. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in Collaboration With the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. JACC 2011; 124. DOI: 10.1161/ CIR.0b013e31823c074e.
19. Vandvik PO, Lincoff AM, Gore JM et al. Primary and Secondary Prevention of Cardiovascular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl.): e637S–68S.

И.С.Явелов 

Кафедра клинической фармакологии ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздравсоцразвития РФ, Москва